![]()
For the financial time-frame ending March 31 2022 VVOS lost money of $-0.25 per share compare to $-0.96 a year ago and EPS fell from $0.43 per share from the prior reporting season.
Revenues fell sharply by -78.419 % to $
3.64 millions from $16.89 millions in the similar reporting season a year ago and sequentially Revenue turned positive from $-9.04 millions.
In the financial time-frame ending March 31 2022 Vivos Therapeutics Inc reported net shortfall of $-5.331 million, instead of deficit of $-20.288 millions in the similar reporting season a year ago.
Vivos Therapeutics Inc is expected to report next financial results on March 30, 2023.